JP7504880B2 - Alk2阻害剤の結晶形 - Google Patents

Alk2阻害剤の結晶形 Download PDF

Info

Publication number
JP7504880B2
JP7504880B2 JP2021522993A JP2021522993A JP7504880B2 JP 7504880 B2 JP7504880 B2 JP 7504880B2 JP 2021522993 A JP2021522993 A JP 2021522993A JP 2021522993 A JP2021522993 A JP 2021522993A JP 7504880 B2 JP7504880 B2 JP 7504880B2
Authority
JP
Japan
Prior art keywords
compound
bmp
subject
fold
compositions described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021522993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512824A5 (cg-RX-API-DMAC7.html
JP2022512824A (ja
Inventor
ベスーン、サラ
ディアス、クリスタ
エイ. エバンス、キャサリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keros Therapeutics Inc
Original Assignee
Keros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keros Therapeutics Inc filed Critical Keros Therapeutics Inc
Publication of JP2022512824A publication Critical patent/JP2022512824A/ja
Publication of JP2022512824A5 publication Critical patent/JP2022512824A5/ja
Priority to JP2024094803A priority Critical patent/JP2024107352A/ja
Application granted granted Critical
Publication of JP7504880B2 publication Critical patent/JP7504880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021522993A 2018-10-26 2019-10-25 Alk2阻害剤の結晶形 Active JP7504880B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024094803A JP2024107352A (ja) 2018-10-26 2024-06-12 Alk2阻害剤の結晶形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751255P 2018-10-26 2018-10-26
US62/751,255 2018-10-26
PCT/US2019/058062 WO2020086963A1 (en) 2018-10-26 2019-10-25 Crystal forms of an alk2 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094803A Division JP2024107352A (ja) 2018-10-26 2024-06-12 Alk2阻害剤の結晶形

Publications (3)

Publication Number Publication Date
JP2022512824A JP2022512824A (ja) 2022-02-07
JP2022512824A5 JP2022512824A5 (cg-RX-API-DMAC7.html) 2022-10-27
JP7504880B2 true JP7504880B2 (ja) 2024-06-24

Family

ID=70330555

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021522993A Active JP7504880B2 (ja) 2018-10-26 2019-10-25 Alk2阻害剤の結晶形
JP2024094803A Pending JP2024107352A (ja) 2018-10-26 2024-06-12 Alk2阻害剤の結晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024094803A Pending JP2024107352A (ja) 2018-10-26 2024-06-12 Alk2阻害剤の結晶形

Country Status (8)

Country Link
US (1) US12071438B2 (cg-RX-API-DMAC7.html)
EP (1) EP3870181B1 (cg-RX-API-DMAC7.html)
JP (2) JP7504880B2 (cg-RX-API-DMAC7.html)
CN (1) CN114269345B (cg-RX-API-DMAC7.html)
AU (1) AU2019364631B2 (cg-RX-API-DMAC7.html)
CA (1) CA3117695A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020086963A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103228B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117695A1 (en) 2018-10-26 2020-04-30 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
EP4294403A4 (en) * 2021-02-18 2024-12-11 Beren Therapeutics P.B.C. METHODS OF TREATMENT OF HETEROZYGOUS AND HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA WITH CYCLODEXTRINS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519059A (ja) 2004-11-04 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なピラゾロ[1,5−α]ピリミジン
JP2013542257A (ja) 2010-11-10 2013-11-21 ノバルティス アーゲー 7−シクロペンチル−2−(5−ピペラジン−1−イル−ピリジン−2−イルアミノ)−7h−ピロロ[2,3−d]ピリミジン−6−カルボン酸ジメチルアミドの塩およびその製造方法
JP2016515119A (ja) 2013-03-14 2016-05-26 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. Bmp阻害剤およびその使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
DE69818675T2 (de) 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth Galaktomannanpolymere und borat enthaltende augenarzneimittel
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20190055192A1 (en) 2004-06-07 2019-02-21 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
EP2954903A1 (en) 2005-02-16 2015-12-16 The General Hospital Corporation Use of bmp antagonists to regulate hepcidin-mediated iron metabolism
US7790407B2 (en) 2005-11-29 2010-09-07 Nevada Cancer Institute Targeting of SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
CN105503882B (zh) * 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
JP7175917B2 (ja) * 2017-04-27 2022-11-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 新規のalk2阻害剤及びbmpシグナル伝達の阻害方法
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
EP3697786B1 (en) 2017-10-18 2022-08-31 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
MX2020005405A (es) 2017-11-24 2020-08-13 Novartis Ag Derivados de piridinona y su uso como inhibidores selectivos de alk-2.
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
AU2019364415A1 (en) 2018-10-23 2021-05-20 Keros Therapeutics, Inc. ALK2 antibodies and methods of use thereof
CA3117695A1 (en) 2018-10-26 2020-04-30 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
MX2022001741A (es) 2019-08-13 2022-03-11 Blueprint Medicines Corp Sal y formas cristalinas de un inhibidor de la cinasa similar a un receptor de activina.
WO2021067670A1 (en) 2019-10-02 2021-04-08 Blueprint Medicines Corporation Process for preparing an activin receptor-like kinase inhibitor
TW202131926A (zh) 2019-11-22 2021-09-01 美商英塞特公司 包含alk2抑制劑及jak2抑制劑的組合療法
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022098821A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating lymphopenia
WO2022099166A1 (en) 2020-11-09 2022-05-12 Keros Therapeutics, Inc. Methods of treating cardiovascular-related disease
US20250034148A1 (en) 2021-11-02 2025-01-30 Keros Therapeutics, Inc. Methods of using alk2 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519059A (ja) 2004-11-04 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なピラゾロ[1,5−α]ピリミジン
JP2013542257A (ja) 2010-11-10 2013-11-21 ノバルティス アーゲー 7−シクロペンチル−2−(5−ピペラジン−1−イル−ピリジン−2−イルアミノ)−7h−ピロロ[2,3−d]ピリミジン−6−カルボン酸ジメチルアミドの塩およびその製造方法
JP2016515119A (ja) 2013-03-14 2016-05-26 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. Bmp阻害剤およびその使用方法

Also Published As

Publication number Publication date
US12071438B2 (en) 2024-08-27
AU2019364631B2 (en) 2025-05-01
ZA202103228B (en) 2025-08-27
WO2020086963A1 (en) 2020-04-30
JP2024107352A (ja) 2024-08-08
EP3870181B1 (en) 2024-08-14
CA3117695A1 (en) 2020-04-30
AU2019364631A1 (en) 2021-06-03
JP2022512824A (ja) 2022-02-07
US20210238185A1 (en) 2021-08-05
EP3870181A4 (en) 2022-07-20
EP3870181A1 (en) 2021-09-01
CN114269345B (zh) 2025-06-27
CN114269345A (zh) 2022-04-01

Similar Documents

Publication Publication Date Title
JP2024107352A (ja) Alk2阻害剤の結晶形
JP5638961B2 (ja) Bmpシグナル伝達経路のインヒビター
US10583143B2 (en) Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
JP6430383B2 (ja) 選択的bmp阻害剤としての縮合複素環化合物
JP7179015B2 (ja) Sestrin-GATOR2相互座用のモジュレーターおよびその使用
US20160115167A1 (en) Bmp inhibitors and methods of use thereof
US20160263117A1 (en) Compositions and methods for cardiovascular disease
CN111164083B (zh) 用于抑制bmp信号传导的新型alk2抑制剂和方法
JP2017536411A (ja) Bmp阻害用組成物及びbmp阻害方法
WO2016011019A1 (en) Compositions and methods for inhibiting bmp
JP2017514793A (ja) Bmp阻害用組成物及びbmp阻害方法
JP2022525506A (ja) ピリダジノン及びその使用法
JP2023516645A (ja) Tead阻害剤としてのヘテロ二官能性分子
JP6909236B2 (ja) キナゾリン誘導体またはその塩およびそれを含む医薬組成物
AU2021352108B2 (en) Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2012157389A1 (ja) DOCK-Aサブファミリー分子によるRac活性化を制御する低分子化合物及びその用途
CN111108083B (zh) 氨基亚甲基环己烷1,3-二酮化合物的用途
CN108658976B (zh) 一类新型吡唑并[4,3-c]吡啶-4(5)-酮布鲁顿激酶抑制剂
AU2007223865A1 (en) Use of pyrazolo[1,5A]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221019

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240612

R150 Certificate of patent or registration of utility model

Ref document number: 7504880

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150